

Association of Viral Load With Disease Severity in Outpatient Children With Respiratory Syncytial Virus Infection

Erika Uusitupa¹, Matti Waris², Terho Heikkinen^{1,3}

¹ Department of Pediatrics, University of Turku, FI-20520 Turku, Finland

² Department of Clinical Microbiology, Turku University Hospital, and Institute of Biomedicine, University of Turku, FI-20520 Turku, Finland

³ Department of Pediatrics, Turku University Hospital, FI-20520 Turku, Finland

Corresponding author: Terho Heikkinen, MD, PhD, Professor of Pediatrics, Department of Pediatrics, University of Turku, FI-20520 Turku, Finland. E-mail: terho.heikkinen@utu.fi
Tel: +358-50-5359095.

Alternate corresponding author: Erika Uusitupa, MD, Department of Pediatrics, University of Turku, FI-20520 Turku, Finland. E-mail: erika.m.uusitupa@utu.fi. Tel: +358-40-8311072.

Summary: In a prospective study of respiratory infections, children with higher respiratory syncytial virus load had significantly longer durations of rhinitis, cough, fever, and any symptoms than those with lower viral load.

Running head: RSV Load and Disease Severity

Word counts: Abstract: 200, Text: 2532

FOOTNOTE PAGE

Financial support

None.

Potential conflicts of interest

T. H. has been a consultant to Janssen, Alios BioPharma, and Sanofi Pasteur. The Hospital District of Southwest Finland (a secondary employer of T. H.) has received a grant from Janssen for an unrelated epidemiologic study of RSV in children. All other authors report no potential conflicts.

Abstract presentation

The results were presented in part as an abstract at the 37th Annual Meeting of the European Society for Paediatric Infectious Diseases, Ljubljana, Slovenia, 6-11 May 2019.

Correspondence and reprint requests

Terho Heikkinen, Department of Pediatrics, University of Turku, FI-20520 Turku, Finland.

E-mail: terho.heikkinen@utu.fi

ABSTRACT

Background. There are scarce data on whether viral load affects the severity of respiratory syncytial virus (RSV) disease in outpatient children.

Methods. We analyzed the association between viral load and disease severity among children who participated in a prospective cohort study of respiratory infections. The children were examined and nasal swabs for the detection of RSV were obtained during each respiratory illness. Quantification of RSV load was based on the cycle threshold (Ct) value. For the primary analysis, the children were divided into 2 groups: higher (Ct <27) and lower viral load (Ct ≥27).

Results. Among 201 episodes of RSV infection, children with higher viral load had significantly longer median durations of rhinitis (8 vs 6 days; $P = .0008$), cough (8 vs 6 days; $P = .034$), fever (2 vs 1 days; $P = .018$), and any symptom (10 vs 8 days; $P = .024$) than those with lower viral load. There were statistically significant negative correlations between the Ct values and the durations of all measured symptoms.

Conclusions. Our findings support the concept that viral load drives the severity of RSV disease in children. Reducing the viral load by RSV antivirals might provide substantial benefits to outpatient children.

Keywords:

Respiratory syncytial virus; children; viral load, disease severity; antiviral agents.

This is a pre-copyedited, author-produced version of an article accepted for publication in [insert journal title] following peer review. The version of record Erika Uusitupa, Matti Waris, Terho Heikkinen, Association of Viral Load With Disease Severity in Outpatient Children With Respiratory Syncytial Virus Infection, *The Journal of Infectious Diseases*, Volume 222, Issue 2, 15 July 2020, Pages 298–304, is available online at: <https://doi.org/10.1093/infdis/jiaa076>.

1 BACKGROUND

2

3 Respiratory syncytial virus (RSV) is a major cause of acute respiratory tract infection in children
4 worldwide [1-5]. More than 3 million children <5 years of age are hospitalized with RSV infection
5 every year, and the annual RSV-associated mortality in this age group has been estimated at
6 118 000 [5]. Although young infants are frequently hospitalized with RSV-associated bronchiolitis,
7 the burden of RSV is substantial also among children treated as outpatients [1, 6, 7]. In the
8 absence of vaccines and antiviral drugs against RSV, the treatment of RSV infections has remained
9 largely supportive [8]. In recent years, however, several candidate RSV vaccines, antivirals, and
10 monoclonal antibodies have been developed and are currently being tested [8, 9].

11

12 One of the main reasons hindering the development of RSV antivirals has been the lack of
13 evidence that higher RSV loads are associated with more severe manifestations of the illness. This
14 question is important because if viral load is a leading factor affecting the clinical RSV illness,
15 reduction of the viral load by use of antiviral agents could be expected to ameliorate the illness.
16 Previous studies assessing the impact of viral load on RSV disease severity have been carried out
17 mainly among hospitalized children, using highly variable study designs and outcomes to measure
18 disease severity. Although several studies have demonstrated a positive correlation between RSV
19 load and the severity of the illness [10-17], a number of studies have failed to show a similar
20 association [18-24].

21

22 The largest numbers of RSV-infected children are treated in the outpatient setting, where the
23 availability of effective RSV antivirals could provide substantial benefits [1, 6]. However, there is

24 little information about the association between RSV load and any measure of disease severity
25 among outpatient children [13]. We sought to determine whether RSV load in naturally infected
26 outpatient children is associated with the duration of symptoms and the rates of complications.
27

28 **METHODS**

29

30 **Subjects**

31 This analysis was based on data from a prospective cohort study of respiratory infections among
32 outpatient children ≤ 13 years of age that was performed during 2 consecutive winter seasons
33 (October-May 2000-2001 and 2001-2002) in Turku, Finland [6, 25]. The participants were recruited
34 through day care centers, family day care, and schools, and there were no exclusion criteria for
35 enrollment. Overall, the study comprised 2231 child-seasons of follow-up. The study protocol was
36 approved by the Ethics Committee of the Hospital District of Southwest Finland, and the study was
37 conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained
38 from the parents or guardians of all participating children before the commencement of the study.
39

40

40 **Study Conduct**

41 During each season, the parents were instructed to bring their child to the study clinic every time
42 the child had fever or signs or symptoms of a respiratory infection. All visits were free of charge,
43 and there was no limit for the number of visits made. The study clinic was open every day. At each
44 visit, a study physician examined the child and filled out a structured medical record that
45 contained the history, signs and symptoms, clinical findings, diagnosis, and treatment. Children

46 without any complications at the first visit were routinely reexamined after 5-7 days and
47 additionally whenever the parents deemed it necessary.

48

49 **Symptom Diaries**

50 Throughout the follow-up period, the parents filled out daily symptom diaries that consisted of
51 charts inquiring about the signs and symptoms of the child, and especially about the objective
52 signs of fever, rhinitis, and cough. The durations of symptoms for this analysis were retrieved from
53 these daily symptom diaries. When calculating the overall duration of illness, all consecutive days
54 on which the child had fever, rhinitis, or cough were included.

55

56 **Virological Assays**

57 During each respiratory infection, regardless of the severity of symptoms or the presence or
58 absence of fever, a nasal swab was obtained for determination of the viral etiology of the illness.
59 All virological analyses were performed at the Department of Virology, University of Turku. The
60 detection of RSV in the specimens was based on both viral culture and reverse-transcription
61 polymerase chain reaction (RT-PCR). Nucleic acids were extracted by using the High Pure Viral
62 Nucleic Acid Kit or the MagNA Pure LC extractor (Roche Diagnostics, Espoo, Finland) according to
63 the manufacturer's protocols. The extracts were stored at -70°C and later analyzed for RSV N gene
64 RNA by RT-PCR [26]. Quantification of the viral load in specimens positive for RSV by RT-PCR was
65 based on determination of the cycle threshold (Ct) value. The Ct value is defined as the calculated
66 cycle number at which the PCR product crosses a threshold of detection, and it provides a
67 semiquantitative measure of viral load. Ct values are inversely proportional to the amount of

68 target nucleic acid in the sample: the lower the Ct value, the greater the amount of target nucleic
69 acid in the specimen.

70

71 **RSV Illnesses Analyzed**

72 Among a total of 302 RSV infections diagnosed in the children, Ct values and full clinical and diary
73 data were available for 268 episodes. To allow for focusing on new-onset RSV illnesses in young
74 children, we limited this analysis to children <10 years of age in whom the maximum duration of
75 respiratory symptoms before sampling at the study clinic was 6 days. During the 2-year study
76 period, 9 children each included in this analysis had 2 separate episodes of RSV illness. For the
77 purposes of this study, these children were considered separate children in the analyses, and they
78 were analyzed in the Ct value and age group that they belonged to at the time of the illness. The
79 final analysis included 201 RSV illnesses in 192 children. The distribution of the Ct values during
80 these episodes is presented in Figure 1; the mean Ct value was 27.7.

81

82 **Statistical Analysis**

83 In the primary analysis to explore the association between viral load and disease severity, we first
84 divided the children into 2 groups on basis of the mean Ct value: higher viral load (Ct value <27)
85 and lower viral load (Ct value \geq 27) (Fig. 1). In a secondary analysis to assess any trends, the 201
86 children were further divided into 3 equal-sized groups according to their Ct value (high,
87 intermediate, and low viral load; n = 67 in each group). Finally, we determined the correlations
88 between the Ct values and the durations of rhinitis, cough, fever, and any symptom among all 201
89 children.

90

91 The unpaired *t* test was used for comparing differences in means, and the Mann–Whitney *U* test
92 for comparing differences in medians between 2 groups. Comparison of differences in means
93 between 3 groups was performed by one-way analysis of variance, and comparison of medians
94 between 3 groups by the Kruskal-Wallis test. Proportions between the groups were compared by
95 the χ^2 test. Spearman’s rank correlation was used to analyze correlations between Ct values and
96 durations of symptoms. Two-sided *P* values of < .05 were considered to indicate statistical
97 significance. All statistical analyses were performed with SPSS Statistics, version 25 (IBM SPSS
98 Statistics).

99

100 **RESULTS**

101

102 **Clinical Characteristics**

103 Of the 201 children with a new-onset RSV illness, 106 (52.7%) children had a Ct value <27 (higher
104 viral load) and 95 (47.3%) had a Ct value \geq 27 (lower viral load). The baseline characteristics of
105 children in these groups are shown in Table 1. The median age of the children was 2.9 years in the
106 higher viral load group and 3.2 years in the lower viral load group (difference of 4 months; *P* = .02).
107 There were no statistically significant differences between the groups in the duration of rhinitis (*P*
108 = .56), cough (*P* = .78), or fever (*P* = .98) prior to viral sampling at the study clinic. Viral culture was
109 positive in 64 (60.4%) children with a Ct value <27, compared with 12 (12.6%) children with a Ct
110 value \geq 27 (*P* < .0001).

111

112 **Duration of Symptoms**

113 In the primary analysis between the 2 groups, children with higher viral load had significantly
114 longer median durations of rhinitis (8 vs 6 days; $P = .0008$), cough (8 vs 6 days; $P = .034$), fever (2 vs
115 1 days; $P = .018$), and any symptom (10 vs 8 days; $P = .024$) than those with lower viral load (Table
116 2).

117

118 In the secondary analysis to assess any trends among children divided into 3 equal-sized groups on
119 basis of their Ct value (high, intermediate, and low viral load), children with high viral load had
120 consistently longest durations of rhinitis, cough, fever, and any symptom, whereas the durations
121 of these symptoms were shortest in children with low viral load (Figure 2). The differences in the
122 mean durations between the 3 groups did not reach statistical significance. However, the
123 differences in the median durations of rhinitis between the 3 groups were statistically significant
124 ($P = .008$).

125

126 The correlations between the Ct value and the duration of various symptoms among all 201
127 children are presented in Figure 3. For all measured outcomes, there was a statistically significant
128 negative correlation between the Ct value and the duration of the symptom, indicating that higher
129 viral load was associated with longer duration of symptoms.

130

131 Because children with higher viral load were younger than those with lower viral load, we further
132 compared the durations of various symptoms between high and low RSV load in different age
133 groups of children (Figure 4). Except for children <2 years of age, there were trends towards
134 longer durations of symptoms among children with higher viral load when adjusted for age group.

135 The differences in the median durations of rhinitis (9 vs 5 days; $P = .0003$) and any symptoms (10
136 vs 8 days; $P = .012$) in the group of children 2-3 years of age were statistically significant.

137

138 **Complications and Antibiotic Treatment**

139 In the primary analysis between the 2 groups, acute otitis media was diagnosed in 56 of 106
140 (52.8%) children in the higher viral load group, compared with 44 of 95 (46.3%) children with
141 lower viral load ($P = .36$). Sixty-three (59.4%) children with higher viral load and 47 (49.5%)
142 children with lower viral load were treated with antibiotics ($P = .16$).

143

144 **DISCUSSION**

145

146 Our study performed in a real-life setting among outpatient children demonstrates that higher RSV
147 load is associated with a longer duration of illness. The main strengths of the study include the
148 prospective follow-up of children who were clinically examined during each episode of respiratory
149 illness, nasal sampling for viruses during each illness regardless of the severity of symptoms, and
150 real-time recording of daily symptoms by the parents. Furthermore, the durations of respiratory
151 symptoms before viral sampling were similar in children with higher and lower viral loads, and the
152 association between the viral load and duration of illness was analyzed and confirmed by several
153 methods.

154

155 To our knowledge, the present analysis consisting of 201 children with RSV infection is the largest
156 one to assess the relationship between RSV load and clinical illness among outpatient children. In
157 a previous study including 30 infants with RSV infection in the community, Houben et al. reported

158 a positive correlation between RSV load and a disease severity score but found no association
159 between viral load and the duration of illness [13]. Their finding of no association may be due to
160 the relatively small sample size, but it is also probable that the method of determining the
161 duration of illness was different from that used in our study because the median duration of RSV
162 illness in their study was only 3 days. In our analysis, the durations of various symptoms were
163 retrieved directly from the symptom diaries that the parents filled out daily during their child's
164 illness, and it is highly likely that those data provided the most accurate information about the
165 duration of symptoms in the children.

166

167 Most previous studies on RSV load and disease severity have been carried out among hospitalized
168 children by using various outcomes to measure disease severity. Although several studies,
169 especially the largest ones, have demonstrated a direct association between viral load and disease
170 severity [10-17], not all of them have found such an association [18-24]. However, there are plenty
171 of potential reasons, ranging from small sample sizes to low sensitivity of the outcomes used for
172 determining severity, for the lack of finding an association between RSV load and disease severity.
173 Therefore, studies failing to show a significant association should not be automatically interpreted
174 to prove the nonexistence of an association.

175

176 Because children treated as outpatients have generally milder illnesses than hospitalized children,
177 the outcomes used for determining disease severity among hospitalized children are not usually
178 applicable to the outpatient setting. As only a small proportion of outpatient children with RSV are
179 eventually hospitalized [6], the duration of illness and the development of complications that are
180 managed in the outpatient setting are relevant indicators of disease severity that also have a

181 direct economic impact on the families in terms of parental work absenteeism and costs of
182 treatment.

183

184 Our study serves as a proof of concept that RSV load is associated with clinical illness also among
185 outpatient children. It is possible that also other factors, for instance host-related ones, play a role
186 in the clinical presentation of RSV illness. Age is a particularly important factor in this context
187 because, as observed also in the present study, young children have higher viral loads than older
188 children or adults [27]. Furthermore, the duration of respiratory illness is generally longer among
189 younger than older children [28]. All in all, it appears that child's age, viral load, and duration of
190 symptoms are all associated with each other. Although it is clear that association does not prove
191 cause and effect, the observed association between viral load and duration of symptoms suggests
192 a mechanism that could be subject to intervention to reduce the severity of RSV illness. It is
193 theoretically possible that effective RSV antiviral agents, especially when started early in the
194 course of the illness, might substantially shorten the duration of the illness and reduce the
195 incidence of complications, analogously to influenza antivirals in the treatment of influenza [29].

196

197 Our study has also some limitations. Although it was so far the largest outpatient study on this
198 topic, the sample size was still modest. This reduced the statistical power to demonstrate
199 differences between smaller subgroups of children and for categorical outcomes such as acute
200 otitis media and antibiotic treatment. The nasal swabs were obtained as part of a clinical follow-up
201 study, and the procedure for the collection of the specimens was not strictly standardized.
202 However, any major variation in the quality of the samples was minimized by two factors: the
203 specimens were collected by few members of the study personnel, and they were all specifically

204 trained to do that prior to the commencement of the study. Moreover, variation in the quality of
205 the specimens would have increased the variability in the Ct values, which would have biased the
206 results in the direction of making it more difficult to demonstrate associations between the viral
207 load and various outcomes.

208
209 In conclusion, our follow-up study among outpatient children provides support for the concept
210 that viral load drives the severity of RSV disease in children. Because it is plausible that reduction
211 of the RSV load by effective antiviral agents could decrease the severity of the illness in children
212 [30, 31], development of such agents can be regarded as a high priority.

213

214

215

216 **ACKNOWLEDGMENTS**

217

218 We are grateful to all participating children and their families and to the entire personnel involved
219 in the performance of the original prospective cohort study.

REFERENCES

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med* **2009**; 360:588-98.
2. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. *Clin Infect Dis* **2012**; 54:1427-36.
3. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. *Pediatrics* **2013**; 132:e341-8.
4. Meissner HC. Viral bronchiolitis in children. *N Engl J Med* **2016**; 374:62-72.
5. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* **2017**; 390:946-58.
6. Heikkinen T, Ojala E, Waris M. Clinical and socioeconomic burden of respiratory syncytial virus infection in children. *J Infect Dis* **2017**; 215:17-23.
7. Diez-Domingo J, Pérez-Yarza EG, Melero JA, et al. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. *BMC Infect Dis* **2014**; 14:544.

8. Mazur NI, Martín-Torres F, Baraldi E, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. *Lancet Respir Med* **2015**; 3:888-900.
9. Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. *Lancet Infect Dis* **2018**; 18:e295-311.
10. Buckingham SC, Bush AJ, DeVincenzo JP. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. *Pediatr Infect Dis J* **2000**; 19:113-7.
11. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. *J Infect Dis* **2005**; 191:1861-8.
12. Fodha I, Vabret A, Ghedira L, et al. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. *J Med Virol* **2007**; 79:1951-8.
13. Houben ML, Coenjaerts FEJ, Rossen JWA, et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. *J Med Virol* **2010**; 82:1266-71.
14. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, DeVincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. *J Infect Dis* **2011**; 204:996-1002.

15. Scagnolari C, Midulla F, Selvaggi C, et al. Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. *Med Microbiol Immunol* **2012**; 201:311-7.
16. Fuller JA, Njenga MK, Bigogo G, et al. Association of the CT values of real-time PCR of viral upper respiratory tract infection with clinical severity, Kenya. *J Med Virol* **2013**; 85:924-32.
17. Hasegawa K, Jartti T, Mansbach JM, et al. Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland. *J Infect Dis* **2015**; 211:1550-9.
18. Wright PF, Gruber WC, Peters M, et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. *J Infect Dis* **2002**; 185:1011-8.
19. Jansen RR, Schinkel J, Dek I, et al. Quantitation of respiratory viruses in relation to clinical course in children with acute respiratory tract infections. *Pediatr Infect Dis J* **2010**; 29:82-4.
20. Franz A, Adams O, Willems R, et al. Correlation of viral load of respiratory pathogens and co-infections with disease severity in children hospitalized for lower respiratory tract infection. *J Clin Virol* **2010**; 48:239-45.

21. Martin ET, Kuypers J, Wald A, Englund JA. Multiple versus single virus respiratory infections: viral load and clinical disease severity in hospitalized children. *Influenza Other Respir Viruses* **2012**; 6:71-7.
22. Mazur NI, Bont L, Cohen AL, et al. Severity of respiratory syncytial virus lower respiratory tract infection with viral coinfection in HIV-uninfected children. *Clin Infect Dis* **2017**; 64:443-50.
23. Rodriguez-Fernandez R, Tapia LI, Yang CF, et al. Respiratory syncytial virus genotypes, host immune profiles, and disease severity in young children hospitalized with bronchiolitis. *J Infect Dis* **2017**; 217:24-34.
24. Garcia-Mauriño C, Moore-Clingenpeel M, Thomas J, et al. Viral load dynamics and clinical disease severity in infants with respiratory syncytial virus infection. *J Infect Dis* **2019**; 219:1207-15.
25. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. *J Infect Dis* **2004**; 190:1369-73.
26. Kutsaya A, Teros-Jaakkola T, Kakkola L, et al. Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life. *Epidemiol Infect* **2016**; 144:1622-33.
27. Heikkinen T, Valkonen H, Waris M, Ruuskanen O. Transmission of respiratory syncytial virus infection within families. *Open Forum Infect Dis* **2015**; 2 (DOI: 10.1093/ofid/ofu118).

28. Silvennoinen H, Huusko T, Vuorinen T, Heikkinen T. Comparative burden of influenza A/H1N1, A/H3N2 and B infections in children treated as outpatients. *Pediatr Infect Dis J* **2015**; 34:1081-5.

29. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. *Clin Infect Dis* **2010**; 51:887-94.

30. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. *N Engl J Med* **2014**; 371:711-22.

31. DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. *N Engl J Med* **2015**; 373:2048-58.

Table 1. Baseline characteristics of the 201 children with RSV illness.

Variable	Ct <27	Ct ≥27
No. of children	106	95
Age group, n (%)		
<2 years	22 (20.8)	14 (14.7)
2-3 years	63 (59.4)	51 (53.7)
4-9 years	21 (19.8)	30 (31.6)
Gender, n (%)		
Girls	53 (50.0)	42 (44.2)
Boys	53 (50.0)	53 (55.8)
Duration of symptoms before viral sampling, days, mean (SD)		
Rhinitis	2.5 (1.4)	2.6 (1.8)
Cough	2.7 (1.3)	2.7 (1.6)
Fever	0.9 (0.9)	0.9 (1.1)
Viral culture, n (%)		
Positive	64 (60.4)	12 (12.6)
Negative	42 (39.6)	83 (87.4)

SD, standard deviation

Table 2. Duration of symptoms in children with higher (Ct <27) and lower (Ct ≥27) viral load.

Symptom	Ct <27 (n = 106)	Ct ≥27 (n = 95)	P
Rhinitis (days)			
Mean (SD)	9.0 (5.2)	6.9 (6.4)	0.012
Median (IQR)	8.0 (6.0-11.0)	6.0 (3.0-10.0)	0.0008
Cough (days)			
Mean (SD)	8.4 (4.7)	7.2 (5.1)	0.079
Median (IQR)	8.0 (6.0-11.0)	6.0 (4.0-10.0)	0.034
Fever (days)			
Mean (SD)	2.3 (2.1)	1.7 (1.9)	0.029
Median (IQR)	2.0 (0.0-4.0)	1.0 (0.0-3.0)	0.018
Any symptom (days)			
Mean (SD)	10.9 (5.7)	9.6 (6.4)	0.12
Median (IQR)	10.0 (8.0-13.0)	8.0 (6.0-12.0)	0.024

SD, standard deviation; IQR, interquartile range

FIGURE LEGENDS

Figure 1.

Distribution of Ct values among the 201 children with RSV illness. Black bars, children with higher viral load (Ct <27, n = 106); grey bars, children with lower viral load (Ct ≥27, n = 95).

Figure 2.

Mean durations of symptoms in children divided into 3 equal-sized groups based on their Ct value (n = 67 in each group). Black bars, children with high viral load (Ct <24.35); grey bars, children with intermediate viral load (Ct 24.35-29.30); dotted bars, children with low viral load (Ct >29.30). *P* values between the 3 groups were calculated by one-way analysis of variance.

Figure 3.

Correlations between the Ct value and the duration of rhinitis (A), cough (B), fever (C), and any symptom (D) among 201 children with RSV illness (Spearman's rank correlation).

Figure 4.

Median durations of symptoms in children adjusted by age: <2 years (n = 36), 2-3 years (n = 114), and 4-9 years (n = 51). Black bars, children with higher viral load (Ct <27); grey bars, children with lower viral load (Ct ≥27). Asterisks indicate statistically significant differences (Mann-Whitney *U* test).

Figure 1.




Figure 2.




Figure 3.




Figure 4.

